MX2021002923A - (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso. - Google Patents
(r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso.Info
- Publication number
- MX2021002923A MX2021002923A MX2021002923A MX2021002923A MX2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A MX 2021002923 A MX2021002923 A MX 2021002923A
- Authority
- MX
- Mexico
- Prior art keywords
- trifluoromethoxy
- piperazine
- carboxylate
- methyl
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731014P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050771 WO2020056105A1 (en) | 2018-09-13 | 2019-09-12 | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002923A true MX2021002923A (es) | 2021-09-08 |
Family
ID=68069873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002923A MX2021002923A (es) | 2018-09-13 | 2019-09-12 | (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso. |
Country Status (28)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2993173T3 (en) | 2018-09-13 | 2024-12-23 | Celgene Corp | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007010076A (es) * | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
| EP3099332A4 (en) * | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| PT3595665T (pt) * | 2017-03-13 | 2024-11-21 | Lundbeck La Jolla Research Center Inc | Inibidores duplos de magl e faah |
| ES2993173T3 (en) | 2018-09-13 | 2024-12-23 | Celgene Corp | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof |
-
2019
- 2019-09-12 ES ES19778721T patent/ES2993173T3/es active Active
- 2019-09-12 RS RS20260687A patent/RS68181B1/sr unknown
- 2019-09-12 FI FIEP19778721.1T patent/FI3849970T3/fi active
- 2019-09-12 IL IL281276A patent/IL281276B2/en unknown
- 2019-09-12 EP EP19778721.1A patent/EP3849970B1/en active Active
- 2019-09-12 MY MYPI2021001295A patent/MY208901A/en unknown
- 2019-09-12 FI FIEP24185102.1T patent/FI4434583T3/fi active
- 2019-09-12 LT LTEPPCT/US2019/050771T patent/LT3849970T/lt unknown
- 2019-09-12 CN CN202410683425.0A patent/CN118561814A/zh active Pending
- 2019-09-12 CA CA3112200A patent/CA3112200A1/en active Pending
- 2019-09-12 WO PCT/US2019/050771 patent/WO2020056105A1/en not_active Ceased
- 2019-09-12 EP EP24185102.1A patent/EP4434583B1/en active Active
- 2019-09-12 MX MX2021002923A patent/MX2021002923A/es unknown
- 2019-09-12 PT PT241851021T patent/PT4434583T/pt unknown
- 2019-09-12 KR KR1020217010747A patent/KR102844245B1/ko active Active
- 2019-09-12 MA MA71839A patent/MA71839B1/fr unknown
- 2019-09-12 AU AU2019337623A patent/AU2019337623B2/en active Active
- 2019-09-12 SM SM20260252T patent/SMT202600252T1/it unknown
- 2019-09-12 ES ES24185102T patent/ES3072981T3/es active Active
- 2019-09-12 BR BR112021004340-3A patent/BR112021004340A2/pt unknown
- 2019-09-12 SI SI201930824T patent/SI3849970T1/sl unknown
- 2019-09-12 JP JP2021514123A patent/JP7405840B2/ja active Active
- 2019-09-12 CN CN201980060119.9A patent/CN113227069B/zh active Active
- 2019-09-12 HR HRP20260757TT patent/HRP20260757T1/hr unknown
- 2019-09-12 DK DK24185102.1T patent/DK4434583T5/da active
- 2019-09-12 PT PT197787211T patent/PT3849970T/pt unknown
- 2019-09-12 US US16/569,578 patent/US11053199B2/en active Active
- 2019-09-12 SM SM20240369T patent/SMT202400369T1/it unknown
- 2019-09-12 HR HRP20241294TT patent/HRP20241294T1/hr unknown
- 2019-09-12 SG SG11202102143RA patent/SG11202102143RA/en unknown
- 2019-09-12 EA EA202190511A patent/EA202190511A1/ru unknown
- 2019-09-12 EP EP26160625.5A patent/EP4768081A2/en active Pending
- 2019-09-12 HU HUE19778721A patent/HUE068147T2/hu unknown
- 2019-09-12 PL PL19778721.1T patent/PL3849970T3/pl unknown
- 2019-09-12 RS RS20241039A patent/RS65967B1/sr unknown
- 2019-09-12 MY MYPI2024007477A patent/MY210363A/en unknown
- 2019-09-12 DK DK19778721.1T patent/DK3849970T3/da active
- 2019-09-12 PL PL24185102.1T patent/PL4434583T3/pl unknown
- 2019-09-12 MA MA53607A patent/MA53607B1/fr unknown
- 2019-09-12 LT LTEP24185102.1T patent/LT4434583T/lt unknown
- 2019-09-12 CN CN202410683444.3A patent/CN118530218A/zh active Pending
-
2021
- 2021-03-10 CL CL2021000596A patent/CL2021000596A1/es unknown
- 2021-03-12 CO CONC2021/0003295A patent/CO2021003295A2/es unknown
- 2021-06-03 US US17/338,182 patent/US11680046B2/en active Active
-
2023
- 2023-05-05 US US18/143,765 patent/US12410133B2/en active Active
-
2025
- 2025-08-06 US US19/292,473 patent/US20260062384A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007432A (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. | |
| MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
| PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
| EP4279071A3 (en) | Novel cannabinoid formulations | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| ZA202403308B (en) | An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide | |
| PH12020500105A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| MY197519A (en) | Notch pathway signaling inhibitor compounds | |
| MX2021006515A (es) | Composiciones de methylobacterium para mejorar el rendimiento del maíz. | |
| MY192425A (en) | Polymorphs | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| PH12020550947A1 (en) | Polymorphs | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| WO2015111085A8 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| MX2023011687A (es) | Formas y composiciones farmaceuticas de ivosidenib. | |
| CA3073766A1 (en) | Process for the preparation of tubulysins and intermediates thereof | |
| SA521421375B1 (ar) | عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها | |
| JOP20200025A1 (ar) | مركبات جديدة تنشط مسار Nrf2 | |
| MY210363A (en) | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof | |
| WO2019136310A3 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| AU2019248350A8 (en) | Process for making sarecycline hydrochloride | |
| MX2022005604A (es) | Metodos para la preparacion de 3-bromo-1-(3-cloropiridin-2-il)-1h- pirazol-5-carboxilato de etilo. | |
| WO2019151967A3 (en) | Water-dispersible tablet formulations comprising deferasirox |